COVID-19 Disease Clinical Trial
Official title:
Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19
This study is to analyze the microglia reaction or direct neurotropic effects of CNS COVID-19 in pathogenesis and brain stem dysfunction in critically ill patients. A microglia-focused, brain-specific 50+ marker CODEX panel is used to assess the neuroinflammatory microenvironment in specific brain regions of deceased COVID-19 patients. The peripheral (cerebrospinal fluid and peripheral blood) cytokine response to SARS-CoV-2 is investigated in regard to CNS affection and consecutive blood brain barrier disruption leading to braininherent neuroinflammatory reactions
This study is to analyze the microglia reaction or direct neurotropic effects of CNS COVID-19 in pathogenesis and brain stem dysfunction in critically ill patients. A microglia-focused, brain-specific 50+ marker CODEX panel is used to assess the neuroinflammatory microenvironment in specific brain regions of deceased COVID-19 patients. The peripheral (cerebrospinal fluid and peripheral blood) cytokine response to SARS-CoV-2 is investigated in regard to CNS affection and consecutive blood brain barrier disruption leading to braininherent neuroinflammatory reactions. Primary endpoints of this project are the multidimensional integration of the analysis from the procedures described above and assessment of the correlation between the gained clinical data (MRI, mental/neurological state), the body fluid proteomic and mass-cytometric analysis (CSF and Plasma proteomics, peripheral blood mass cytometry) and the CODEX analysis of defined brain regions on autopsy specimens. Non-critically ill COVID-19 patients and critically ill COVID-19 patients needing mechanical ventilation at the ICU are included. Autopsy specimens from medulla oblongata, cortex, cerebellum and olfactory bulb are investigated, including only tissue samples, which have been submitted to the Institute of Pathology, University Hospital Basel. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04984408 -
Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
|
Phase 3 | |
| Terminated |
NCT04642638 -
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04587323 -
VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
|
||
| Completed |
NCT04682873 -
A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus
|
Phase 3 | |
| Completed |
NCT04359212 -
Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19
|
||
| Completed |
NCT05603130 -
Epidemiologic Register on Diabetes and COVID-19 in Tunisia
|
||
| Completed |
NCT04830800 -
A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC
|
Phase 1/Phase 2 | |
| Completed |
NCT04757792 -
Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU
|
||
| Active, not recruiting |
NCT04417257 -
Study of LAU-7b for the Treatment of COVID-19 Disease in Adults
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04522037 -
Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients
|
||
| Completed |
NCT04446377 -
A Study of LAM-002A for the Prevention of Progression of COVID-19
|
Phase 2 | |
| Active, not recruiting |
NCT04969172 -
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection
|
Phase 2 | |
| Completed |
NCT04347369 -
A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease
|
||
| Completed |
NCT04366024 -
A Novel Nomogram to Predict Severity of COVID-19
|
||
| Completed |
NCT04787510 -
COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection
|
||
| Completed |
NCT05329220 -
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
|
Phase 3 | |
| Active, not recruiting |
NCT05077267 -
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
|
Phase 2 | |
| Active, not recruiting |
NCT04371354 -
Outcomes of Covid-19 Protective Measures in Endoscopy
|
||
| Not yet recruiting |
NCT04779359 -
Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease
|